Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes
Kuo CC, Chuang MH, Li CH, et al.
Diabetologia. Pub. online 5 Jun 2025.
Leggi
Breaking news
Income and severe hypoglycemia in type 2 diabetes
Kim M, Han K, Lee K, et al.
JAMA Netw Open. 2025;8(6):e2513293.
Leggi
Biomarkers in diabetic nephropathy: a comprehensive review of their role in early detection and disease progression monitoring
Wani ZA, Ahmed S, Saleh A, et al.
Diabetes Res Clin Pract. 2025:112292.
Leggi
AIFA: Ridurre l’impatto ambientale dei farmaci: in un Report le misure proposte dal gruppo di lavoro europeo
6 giugno 2025
Leggi
EMA: New guideline on inclusion of pregnant and breastfeeding individuals in clinical trials
4 giugno 2025
Leggi
EMA: PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. Treatment with semaglutide should be stopped if NAION occurs 6 giugno 2025
6 giugno 2025
Leggi
Kidney disease: the forgotten legacy of type 1 diabetes
Thomas MC, Zoungas S, Hanssen NMJ, et al.
Diabetes Care. 2025:dci250028.
Leggi
Copenhagen declaration: a blueprint for diabetes care and research in an interconnected world
Beyh YS, Bergman M, Chan JCN et al.
The Global Diabetes Forum (GDF). Pub. online 30 May 2025.
Leggi
Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association
Cusi K, Abdelmalek MF, Apovian CM, et al.
Diabetes Care. 2025:dci240094.
Leggi